Intismeran autogene (V940 / mRNA-4157)
Phase 3Evidence reviewed by an editor
Phase 3 INTerpath-001 (NCT05933577) met its primary recurrence-free survival endpoint, announced Aug. 19, 2026; the companies say they will engage regulators on filings (company release).
What this stage means
Phase 3 trials test whether a treatment works better than, or as well as, existing care in larger groups of people — usually the last step before a regulator decides.
A development stage describes where the evidence stands for one specific use. It does not mean the product works for everyone, is available everywhere, or will succeed commercially.